Related Experiment Video

Updated: Jan 1, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.5K

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report

Dylan Fortman1, Rochell Issa1, Laura Stanbery1

  • 1College of Medicine and Life Sciences, University of Toledo, Toledo, OH, United States.

Gynecologic Oncology Reports
|December 24, 2019
PubMed

Insights

Advanced cervical cancer in women can be treated with targeted HER2 therapy, showing sustained response in a metastatic case. This approach offers a new avenue for patients progressing on standard treatments.

Area of Science:

  • Oncology
  • Genomics

Background:

  • Cervical cancer is a leading cause of death in women, particularly when metastatic.
  • Standard chemotherapy offers limited survival benefits for advanced cervical cancer.
  • Next-generation sequencing (NGS) enables personalized cancer treatments.

Observation:

  • A 46-year-old female with advanced cervical adenocarcinoma and lung metastases was identified with a HER2 mutation.
  • The patient received first and second-line HER2-targeted therapy.

Findings:

  • The patient demonstrated a sustained disease response to HER2-targeted therapy.
  • HER2-targeted therapy shows promise in managing advanced, metastatic cervical cancer.

Implications:

  • NGS and targeted therapy represent a significant advancement in treating refractory cervical cancer.
  • Further research into HER2-targeted therapies could improve outcomes for advanced cervical cancer patients.
  • Understanding the economic impact of NGS and targeted treatments is crucial for broader implementation.
Keywords:
Cervical cancerCisplatinHER2ImmunotherapyPrecision MedicineTrastuzumab

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K